Lund, Sweden, 2013-11-22 08:45 CET (GLOBE NEWSWIRE) --
FUJIFILM RI Pharma Co., Ltd. officially released the updated version Bonenavi 2.0, all according to plan. Bonenavi is the Japanese version of EXINI boneTM.
This is a result of the collaborative development between EXINI Diagnostics and FUJIFILM RI Pharma together with several Japanese Hospitals and Universities. It started in 2012 and all involved are very pleased with the cooperation:
Toshiya Morita, Marketing Director, FUJIFILM RI Pharma -"We are happy to release a completely new version of Bonenavi and made more than 100 installations in Japanese hospital the first week. The collaboration with EXINI worked very well. The company was very adaptive to Japanese users needs, and delivered on time throughout the whole process. I believe that Bonenavi 2.0 is useful for many doctors." Dr. Kenichi Nakajima, Kanazawa University -"The new Bonenavi 2.0 is a major improvement over Bonenavi 1.0 with further amelioration in diagnostic accuracy. Japanese doctors and patients will benefit of the upgrade. The utility of Bonenavi could be further extended to breast cancer and other cancer types, as well as prostatic cancer." Magnus Aurell, CEO, EXINI Diagnostics -"FUJIFILM RI Pharma’s support together with the hard work of Japanese physicians and technicians have made it possible to make important improvements and introduce completely new functions in the product for the Japanese market.
In the same time, the congress ”The 53rd Annual Scientific Meeting of the Japanese Society of Nuclear Medicine and The 33rd Annual Meeting of the Japanese Society of Nuclear Medicine Technology” took place in Fukuoka City, Japan. At the congress there were several presentations showing the usefulness of Bonenavi.
For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
